Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study
Serena Yun‐Chen Tsai, Wanda Phipatanakul, Elena B. Hawryluk, Michiko K. Oyoshi, Lynda C. Schneider, Kevin Sheng‐Kai
Topics & Concepts
MedicineDupilumabAtopic dermatitisRuxolitinibJanus kinase inhibitorInternal medicineDermatologyPopulationAdverse effectTofacitinibMyelofibrosisEnvironmental healthRheumatoid arthritisBone marrowDermatology and Skin DiseasesPsoriasis: Treatment and PathogenesisInflammasome and immune disorders